Looking at those case studies of drugs with positive phase 2's that failed phase 3 (a few on that list are medical devices) most either didn't repeat the same endpoint on phase 3 as phase 2 and/or showed significant safety issues in phase 3. Neither of those apply to leronlimab obviously, provided the FDA agrees to a phase 3 with NEWS2 as the primary.

I'm a little pessimistic about an EUA after the phase 2 but this is a very unusual time and we did hit an important endpoint.